Literature DB >> 33405418

CORR Insights®: Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors.

Lars Morawietz1.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 33405418      PMCID： PMC8133039          DOI： 10.1097/CORR.0000000000001626

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.755


× No keyword cloud information.
  7 in total

1.  Development of a Novel Orthotopic Primary Human Chordoma Xenograft Model: A Relevant Support for Future Research on Chordoma.

Authors:  Henri Salle; Marc Pocard; Jacqueline Lehmann-Che; Sylvie Bourthoumieu; François Labrousse; Cynthia Pimpie; Leslie Lemnos; Jean-Pierre Guichard; Sebastien Froelich; Homa Adle-Biassette
Journal:  J Neuropathol Exp Neurol       Date:  2020-03-01       Impact factor: 3.685

2.  Defective HLA Class I Expression and Patterns of Lymphocyte Infiltration in Chordoma Tumors.

Authors:  Shalin S Patel; Sjoerd P Nota; Francesco Sabbatino; G Petur Nielsen; Vikram Deshpande; Xinhui Wang; Soldano Ferrone; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2021-06-01       Impact factor: 4.755

Review 3.  Advances in immune checkpoint inhibitors for bone sarcoma therapy.

Authors:  Pichaya Thanindratarn; Dylan C Dean; Scott D Nelson; Francis J Hornicek; Zhenfeng Duan
Journal:  J Bone Oncol       Date:  2019-01-29       Impact factor: 4.072

Review 4.  Combination therapy: Future directions of immunotherapy in small cell lung cancer.

Authors:  Wei Huang; Jia-Jia Chen; Rui Xing; Yue-Can Zeng
Journal:  Transl Oncol       Date:  2020-10-13       Impact factor: 4.243

5.  Patient-derived organoids as a potential model to predict response to PD-1/PD-L1 checkpoint inhibitors.

Authors:  Giosue Scognamiglio; Annarosaria De Chiara; Antonina Parafioriti; Elisabetta Armiraglio; Flavio Fazioli; Michele Gallo; Laura Aversa; Rosa Camerlingo; Francesco Cacciatore; Gianluca Colella; Roberto Pili; Filomena de Nigris
Journal:  Br J Cancer       Date:  2019-10-31       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.